Annual EBITDA
-$57.04 M
+$1.26 M+2.16%
December 31, 2023
Summary
- As of February 7, 2025, MIST annual EBITDA is -$57.04 million, with the most recent change of +$1.26 million (+2.16%) on December 31, 2023.
- During the last 3 years, MIST annual EBITDA has fallen by -$6.43 million (-12.70%).
- MIST annual EBITDA is now -590.54% below its all-time high of -$8.26 million, reached on December 31, 2017.
Performance
MIST EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$8.51 M
-$61.00 K-0.72%
September 30, 2024
Summary
- As of February 7, 2025, MIST quarterly EBITDA is -$8.51 million, with the most recent change of -$61.00 thousand (-0.72%) on September 30, 2024.
- Over the past year, MIST quarterly EBITDA has increased by +$5.71 million (+40.13%).
- MIST quarterly EBITDA is now -1257.96% below its all-time high of $735.00 thousand, reached on June 30, 2021.
Performance
MIST Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$39.14 M
+$5.71 M+12.72%
September 30, 2024
Summary
- As of February 7, 2025, MIST TTM EBITDA is -$39.14 million, with the most recent change of +$5.71 million (+12.72%) on September 30, 2024.
- Over the past year, MIST TTM EBITDA has increased by +$18.33 million (+31.90%).
- MIST TTM EBITDA is now -820.36% below its all-time high of -$4.25 million, reached on March 31, 2018.
Performance
MIST TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
MIST EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +2.2% | +40.1% | +31.9% |
| 3 y3 years | -12.7% | +42.9% | +33.9% |
| 5 y5 years | -139.5% | +42.9% | +33.9% |
MIST EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -32.7% | +2.2% | -0.7% | +49.6% | at high | +36.9% |
| 5 y | 5-year | -32.7% | +2.2% | -1258.0% | +54.9% | -19.9% | +38.5% |
| alltime | all time | -590.5% | +2.2% | -1258.0% | +54.9% | -820.4% | +38.5% |
Milestone Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$8.51 M(+0.7%) | -$39.14 M(-12.7%) |
| Jun 2024 | - | -$8.45 M(-10.6%) | -$44.85 M(-13.1%) |
| Mar 2024 | - | -$9.45 M(-25.7%) | -$51.60 M(-9.5%) |
| Dec 2023 | -$57.04 M(-2.2%) | -$12.73 M(-10.5%) | -$57.04 M(-0.8%) |
| Sep 2023 | - | -$14.22 M(-6.5%) | -$57.48 M(-0.5%) |
| Jun 2023 | - | -$15.20 M(+2.0%) | -$57.79 M(-2.4%) |
| Mar 2023 | - | -$14.90 M(+13.2%) | -$59.21 M(+1.5%) |
| Dec 2022 | -$58.30 M(+35.6%) | -$13.16 M(-9.4%) | -$58.34 M(-6.0%) |
| Sep 2022 | - | -$14.53 M(-12.6%) | -$62.07 M(+0.5%) |
| Jun 2022 | - | -$16.62 M(+18.5%) | -$61.79 M(+39.1%) |
| Mar 2022 | - | -$14.02 M(-17.0%) | -$44.43 M(+3.4%) |
| Dec 2021 | -$42.98 M | -$16.89 M(+18.6%) | -$42.98 M(+23.4%) |
| Sep 2021 | - | -$14.25 M(-2038.6%) | -$34.82 M(+6.7%) |
| Jun 2021 | - | $735.00 K(-105.8%) | -$32.63 M(-29.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2021 | - | -$12.57 M(+43.9%) | -$46.45 M(-8.2%) |
| Dec 2020 | -$50.61 M(-12.5%) | -$8.74 M(-27.6%) | -$50.61 M(-16.7%) |
| Sep 2020 | - | -$12.06 M(-7.8%) | -$60.74 M(-2.7%) |
| Jun 2020 | - | -$13.08 M(-21.8%) | -$62.40 M(-2.0%) |
| Mar 2020 | - | -$16.73 M(-11.3%) | -$63.65 M(+10.0%) |
| Dec 2019 | -$57.84 M(+142.9%) | -$18.87 M(+37.6%) | -$57.84 M(+17.9%) |
| Sep 2019 | - | -$13.72 M(-4.3%) | -$49.08 M(+19.3%) |
| Jun 2019 | - | -$14.33 M(+31.2%) | -$41.15 M(+35.0%) |
| Mar 2019 | - | -$10.93 M(+8.1%) | -$30.49 M(+28.0%) |
| Dec 2018 | -$23.81 M(+188.3%) | -$10.11 M(+74.8%) | -$23.81 M(+73.7%) |
| Sep 2018 | - | -$5.78 M(+57.4%) | -$13.71 M(+72.9%) |
| Jun 2018 | - | -$3.67 M(-13.6%) | -$7.93 M(+86.4%) |
| Mar 2018 | - | -$4.25 M | -$4.25 M |
| Dec 2017 | -$8.26 M | - | - |
FAQ
- What is Milestone Pharmaceuticals annual EBITDA?
- What is the all time high annual EBITDA for Milestone Pharmaceuticals?
- What is Milestone Pharmaceuticals annual EBITDA year-on-year change?
- What is Milestone Pharmaceuticals quarterly EBITDA?
- What is the all time high quarterly EBITDA for Milestone Pharmaceuticals?
- What is Milestone Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Milestone Pharmaceuticals TTM EBITDA?
- What is the all time high TTM EBITDA for Milestone Pharmaceuticals?
- What is Milestone Pharmaceuticals TTM EBITDA year-on-year change?
What is Milestone Pharmaceuticals annual EBITDA?
The current annual EBITDA of MIST is -$57.04 M
What is the all time high annual EBITDA for Milestone Pharmaceuticals?
Milestone Pharmaceuticals all-time high annual EBITDA is -$8.26 M
What is Milestone Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, MIST annual EBITDA has changed by +$1.26 M (+2.16%)
What is Milestone Pharmaceuticals quarterly EBITDA?
The current quarterly EBITDA of MIST is -$8.51 M
What is the all time high quarterly EBITDA for Milestone Pharmaceuticals?
Milestone Pharmaceuticals all-time high quarterly EBITDA is $735.00 K
What is Milestone Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, MIST quarterly EBITDA has changed by +$5.71 M (+40.13%)
What is Milestone Pharmaceuticals TTM EBITDA?
The current TTM EBITDA of MIST is -$39.14 M
What is the all time high TTM EBITDA for Milestone Pharmaceuticals?
Milestone Pharmaceuticals all-time high TTM EBITDA is -$4.25 M
What is Milestone Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, MIST TTM EBITDA has changed by +$18.33 M (+31.90%)